JP2022532519A5 - - Google Patents
Info
- Publication number
- JP2022532519A5 JP2022532519A5 JP2021565055A JP2021565055A JP2022532519A5 JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5 JP 2021565055 A JP2021565055 A JP 2021565055A JP 2021565055 A JP2021565055 A JP 2021565055A JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- composition according
- antibody
- lymphoma
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025166185A JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のnk細胞を有する患者における抗cd19療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19172495.4 | 2019-05-03 | ||
| EP19172495 | 2019-05-03 | ||
| PCT/EP2020/062289 WO2020225196A1 (en) | 2019-05-03 | 2020-05-04 | Anti-cd19 therapy in patients having a limited number of nk cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166185A Division JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のnk細胞を有する患者における抗cd19療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532519A JP2022532519A (ja) | 2022-07-15 |
| JP2022532519A5 true JP2022532519A5 (cg-RX-API-DMAC7.html) | 2023-05-09 |
Family
ID=66647010
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565055A Pending JP2022532519A (ja) | 2019-05-03 | 2020-05-04 | 限られた数のnk細胞を有する患者における抗cd19療法 |
| JP2025166185A Pending JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のnk細胞を有する患者における抗cd19療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166185A Pending JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のnk細胞を有する患者における抗cd19療法 |
Country Status (15)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| ES2981046T3 (es) | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2021084062A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗cd19抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| ES2981046T3 (es) * | 2016-05-30 | 2024-10-07 | Incyte Corp | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
-
2020
- 2020-05-04 CN CN202080044363.9A patent/CN114072424A/zh active Pending
- 2020-05-04 AU AU2020267823A patent/AU2020267823A1/en active Pending
- 2020-05-04 SG SG11202111343TA patent/SG11202111343TA/en unknown
- 2020-05-04 US US17/605,285 patent/US20220242952A1/en active Pending
- 2020-05-04 WO PCT/EP2020/062289 patent/WO2020225196A1/en not_active Ceased
- 2020-05-04 EP EP20722336.3A patent/EP3962943A1/en active Pending
- 2020-05-04 EA EA202193024A patent/EA202193024A1/ru unknown
- 2020-05-04 MX MX2021013101A patent/MX2021013101A/es unknown
- 2020-05-04 PH PH1/2021/552743A patent/PH12021552743A1/en unknown
- 2020-05-04 KR KR1020217039415A patent/KR20220007087A/ko active Pending
- 2020-05-04 MA MA055794A patent/MA55794A/fr unknown
- 2020-05-04 MY MYPI2021006219A patent/MY209449A/en unknown
- 2020-05-04 JP JP2021565055A patent/JP2022532519A/ja active Pending
- 2020-05-04 CA CA3137664A patent/CA3137664A1/en active Pending
-
2021
- 2021-10-12 IL IL287203A patent/IL287203A/en unknown
-
2025
- 2025-10-02 JP JP2025166185A patent/JP2026004466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zitvogel et al. | Immunological off-target effects of imatinib | |
| Cho et al. | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside | |
| US20200147084A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| JP2023517243A5 (cg-RX-API-DMAC7.html) | ||
| JP2023093495A5 (cg-RX-API-DMAC7.html) | ||
| PT1616572E (pt) | Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica | |
| JP2004512262A5 (cg-RX-API-DMAC7.html) | ||
| JP2022523740A5 (cg-RX-API-DMAC7.html) | ||
| CN107073122A (zh) | 恶性肿瘤的联合治疗 | |
| JP6764017B2 (ja) | がんの処置での使用のためのコビシスタット | |
| JP2019519770A5 (cg-RX-API-DMAC7.html) | ||
| RU2019138222A (ru) | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли | |
| CN112074271A (zh) | 用于治疗淋巴瘤的方法 | |
| Zic et al. | The North American experience with photopheresis | |
| JP2018535996A5 (cg-RX-API-DMAC7.html) | ||
| AU2016311136A1 (en) | Combinations and uses thereof | |
| Chou et al. | Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients | |
| WO2021124096A1 (en) | Once daily cancer treatment regimen with a prmt5 inhibitor | |
| Parisi et al. | Acute myelogenous leukemia: advances and limitations of treatment | |
| RU2013106216A (ru) | Биомаркеры хронической лимфоцитарной лейкемии | |
| Chavez et al. | ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)–Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study | |
| Pan et al. | DDDR-18. SINGLE-CELL FUNCTIONAL GENOMIC ANALYSIS OF PHARMACOLOGIC RESPONSES IN NF1 MUTANT GLIOBLASTOMA REVEALS DISTINCT MECHANISMS OF ACTION FOR MEK AND SHP2 INHIBITION | |
| Rathore et al. | The chronic leukemias: current and novel therapeutic approaches | |
| CN117279640A (zh) | 使用组合疗法治疗b细胞淋巴瘤的方法 | |
| Wilson | growing treatment Options for Follicular lymphoma |